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Summary Introduction: Although vagus nerve stimulation (VNS) therapy is approved
for the treatment of partial onset seizures, its efﬁcacy for generalized seizures has
not been fully evaluated. This Investigational Device Exemption assessed the out-
come of VNS therapy among patients with generalized epilepsy syndromes.
Methods: Sixteen patients with pharmacoresistant generalized epilepsy syndromes
and stable antiepileptic drug (AED) regimens were implanted with the VNS therapy
device and were evaluated for changes in seizure frequency and type between base-
line and follow-up of 12—21 months. Results: The patients experienced a statistically
signiﬁcant overall median seizure frequency reduction of 43.3% (P = 0.002, Wilcoxon
signed rank test) after 12—21 months of VNS therapy. Types of seizures that may in-
volve a fall or collapse decreased with reductions in the frequency of myoclonic (60%
reduction, n = 9; P = 0.016, Wilcoxon signed rank test), tonic (75% reduction, n = 8,
NS), atonic (98.6%, n = 3, NS), and clonic seizures (86.7%, n = 1, NS). Conclusion: The
beneﬁts of reduced seizure frequency and reduced risk of injury merit consideration
of VNS therapy for patients with pharmacoresistant generalized seizure syndromes.
© 2003 BEA Trading Ltd. Published by Elsevier B.V. All rights reserved.
Introduction
When vagus nerve stimulation (VNS) therapy (Cy-
beronics; Houston, TX) was approved by the US
Food and Drug Administration (FDA) in 1997, the
system was ‘‘indicated for use as an adjunctive
therapy in reducing the frequency of seizures
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in adults and adolescents over 12 years of age
with partial onset seizures that are refractory to
antiepileptic medications.’’1 VNS therapy is deliv-
ered by a pulse generator implanted in the chest
and connected to the left vagus nerve with a lead
ending with electrodes. The stimulation is deliv-
ered in ON and OFF cycles around the clock at
an intensity determined and set by the clinician.
The patient or caregiver who senses an oncoming
seizure may activate an extra burst of stimulation
with a hand-held magnet in an attempt to abort
or diminish the seizure. Results of the pivotal ran-
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domized clinical trial (E05) after 12 months5 of VNS
therapy for partial-onset seizures as well as 3-year
follow-up for 440 evaluable patients8 (E01—E05)
are well documented. Since FDA approval, several
studies have suggested that VNS therapy may also
be effective for patients with pharmacoresistant
generalized epilepsy syndromes.4,6,7 We undertook
this study to examine the outcome of VNS therapy
among adult patients with well-documented, phar-
macoresistant, generalized epilepsy syndromes.
Methods
The University of Washington Human Subjects Com-
mittee approved this study and the US FDA granted
an Investigational Device Exemption. Inclusionary
criteria required a diagnosis of generalized epilepsy
syndrome, either idiopathic or symptomatic (in
accordance with ILAE classiﬁcation).2,3 Diagnosis
was on the basis of clinical data, MRI ﬁndings, and
long-term EEG-video monitoring. Participants had
at least six pharmacoresistant seizures per month
during the 3 months before enrollment in the study,
were aged 12 years or older, and on a stable regi-
men of one or more antiepileptic drugs (AEDs).
Patients were excluded from the study for any
progressive neurologic disease other than epilepsy
or a history of active cardiac or pulmonary dis-
ease; peptic ulcer; cervical vagotomy; gastric
surgery; substance abuse within the previous year;
self-mutilation; suicidal attempts; general anes-
thesia within the previous 3 months; using an inves-
tigational device or drug; previous VNS therapy or
brain stimulation; swallowing dysfunction or hospi-
talization for aspiration pneumonia; likelihood of
requiring hospitalization or MRI with body coil; or
being on the ketogenic diet during the 3 months
immediately before enrollment.
Study protocol
At the ﬁrst clinic visit, investigators obtained a
detailed patient history and performed a clinical
examination. Patients meeting inclusionary crite-
ria were followed for 3 months to obtain baseline
seizure frequencies. Each patient or caregiver
maintained daily diaries of seizure counts for each
seizure type. To help ensure the accuracy of seizure
diaries, caregivers viewed videotaped episodes of
the patient experiencing each type of seizure.
After the baseline phase, the VNS therapy pulse
generator and leads were implanted and VNS ther-
apy was initiated 1 week later. Standard settings
were employed: 30Hz, 500s, 30 s ON, 5min OFF,
magnet ON at 500s. The output current, initially
set at 0.25mA, was increased weekly by 0.25mA
increments to 1.25mA. After the ramp-up phase,
patients were seen monthly to collect seizure in-
formation and interrogate the pulse generator. VNS
therapy setting was adjusted, if necessary, to allow
for side effects. Output current was increased if
greater response was desired and stronger stimula-
tion could be tolerated. Patients were maintained
on stable AED regimens.
Data analyses
Data were collected regarding clinical character-
istics and changes in seizure frequency. Percent
change in seizure frequency between baseline and
follow-up were calculated for all seizures and by
seizure type. Monthly seizure counts were 3-month
averages both pre- and post-implantation. Upper
and lower limits of changes in seizure frequency
were bounded at 100 and −100%, respectively.
Wilcoxon’s signed rank tests for non-parametric
data were used to test hypotheses of no change in
seizure frequency. Values of P ≤ 0.05 were consid-
ered statistically signiﬁcant. All analyses were per-
formed using SAS®, Version 8.2 (SAS Institute, Cary,
NC) or S-PLUS 2000®, Release 3 (Mathsoft, Inc.).
Results
Of the 16 patients enrolled in the study, 8 patients
had idiopathic (IGE) and 8 had symptomatic gener-
alized epilepsy (SGE) syndromes. Ages of the 9 men
and 7 women ranged from 20 to 66 years and aver-
aged 36 years (S.D.± 11.3). Average age at seizure
onset was 7.5 years (S.D.± 4.8) and epilepsy dura-
tion ranged from 6 to 49 years (Table 1). Most of the
patients were not employed outside their homes,
all lived with some type of caregiver, and all had
some degree of cognitive impairment. Follow-up af-
ter implantation ranged from 12 to 21 months.
Before enrollment, patients had tried and dis-
continued for lack of effectiveness a mean of 7.5
AEDs (range, 2—15). Gabapentin, carbamazepine,
phenobarbital, and diazapam were the most fre-
quently tried and discontinued AEDs. During the
study, patients took a mean of 2.69 AEDs (range,
1—5) with dosages remaining stable. Valproic acid,
lamotrigine, lorazepam, and topiramate were most
frequently prescribed.
Table 1 lists patient demographics, clinical char-
acteristics, and changes in seizure frequency. Fig. 1
provides median percentages of seizure reductions
from baseline: overall, by syndrome, and by type
with marked decreases in seizure types featuring
patient falls. Fig. 2 shows changes in monthly
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Table 1 Clinical characteristics of patients and outcome after VNS therapy by seizure type.
Patient Age Sex Onset Syndrome Seizure type Seizures per month
Baselinea Post-VNS
1 39 F 0 SGE Tonic 0.3 0.0
Myoclonic 23.0 14.0
2 40 F 13 IGE GTC 4.0 1.6
Myoclonic 4.0 1.6
Absence 10.0 1.0
3 35 F 5 SGE GTC 30.0 3.0
Tonic 210.0 12.0
Atonic 30.0 0.0
Absence >90.0 >90.0
4 40 M 7 SGE GTC 60.0 1.8
Tonic 90.0 2.4
Clonic 30.0 4.0
Atonic 12.0 4.0
5 49 M 7 IGE GTC 1.0 0.5
Myoclonic 8.0 5.0
Absence 30.0 0.0
6 27 M 7 SGE GTC 8.0 5.3
Tonic 24.0 50.0
Absence >90.0 >90.0
7 39 M 11 IGE GTC 1.0 1.0
Myoclonic 20.0 0.0
Absence >30.0 >30.0
8 40 M 8 IGE GTC 0.2 1.5
Atonic 180.0 2.5
Myoclonic >500.0 30.0
Absence 40.0 3.0
9 20 F 14 IGE GTC 40.0 20.0
Absence 3.0 3.0
10 66 M 17 SGE GTC 3.0 4.0
Tonic 300.0 90.0
11 39 M 6 IGE GTC 0.5 0.5
Myoclonic 60.0 77.0
12 23 M 10 IGE Myoclonic >500.0 >500.0
13 39 M 6 IGE GTC 9.0 6.0
Myoclonic 60.0 0.0
Absence >500.0 >500.0
14 24 F 0 SGE GTC 20.0 12.0
Tonic 15.0 16.0
15 32 F 1 SGE GTC 0.3 0.0
Tonic 5.0 1.0
Myoclonic 1.0 0.0
Absence 5.0 0.0
16 26 F 8 SGE GTC 12.0 28.0
Tonic 17.0 20.0
Absence 90.0 76.0
IGE: idiopathic generalized epilepsy; SGE: symptomatic generalized epilepsy; GTC: generalized tonic—clonic.
a Some patients reported seizure frequencies as exceeding a speciﬁc number. Such reports are indicated with a
‘‘>’’ symbol in the table. Data analyses were performed conservatively, using the number given, e.g. >500 was
treated as 500.
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Figure 1 Median percent reduction in seizure frequency between baseline and follow-up by seizure syndrome and seizure type. Median percent reduction in
seizure frequency of all seizures and all patients, by syndrome, and by seizure type. ∗Statistically signiﬁcant (P ≤ 0.05) Wilcoxon’s signed rank test. Abbreviations:
IGE–—idiopathic generalized epilepsy; SGE–—symptomatic generalized epilepsy; GTC–—generalized tonic—clonic. The difference in seizure frequency reductions was
not statistically signiﬁcant between the two epilepsy syndromes (P = 0.958, Wilcoxon rank sum test).
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Figure 2 Change in total seizure frequency pre-VNS vs. follow-up. Seizure reductions of all 16 patients as well as
median reduction plotted from pre-VNS through follow-up.
seizure frequency. No patients reported any new
types of seizures.
At the end of the study, 43.8% (7 of 16) of the
patients had at least a 50% reduction in overall
seizure frequency as compared with baseline, in-
cluding 31.3% (5 of 16) with at least a 75% reduction
and 18.8% (3 of 16) with at least a 90% reduction.
An additional 18.8% (3 of 16) reported seizures re-
duced by 25—49%, and another 31.3% (5 of 16) re-
ported changes ranging from decreases of less than
25% to increases of less than 25%. Seizure frequency
increased at least 25% in one patient.
Themagnet was useful in aborting or reducing the
severity of some seizures in 25% (4 of 16 patients).
Adverse events associated with VNS therapy, voice
change or hoarseness (14 patients), throat pain with
stimulation (3), swallowing complaints (2), cough
(1), were mild and resolved after several weeks.
Discussion
The reduction in overall seizure frequency in our
study supports previous reports of the effective-
ness of VNS therapy for both generalized and par-
tial seizures. At follow-up of 12—21 months, the
patients in our study of generalized seizures ex-
perienced a 43.3% median reduction in seizure
frequency. This reduction is similar to the 46% me-
dian reduction noted among the 24 patients with
generalized seizures after 3 months of VNS therapy
during the open-label (E04) clinical trial.6 Although
our study involved generalized seizures, the me-
dian seizure reduction was similar to the 45% noted
for 114 patients at 12 months after the initial
double-blind portion of the E05 clinical trial investi-
gating VNS therapy for partial-onset seizures.5 The
wide range of endpoints and numbers of patients
preclude a precise comparison of these studies,
but the similarity in reduction of seizure frequency
of both partial-onset and generalized seizures is
notable.
Three patients in our study experienced seizure
frequency reductions of 90% or more, which is espe-
cially impressive, considering the established phar-
macoresistance of these patients. Also important
to the clinician were the marked decreases in the
frequency of seizures that may involve a fall or col-
lapse. The nine patients withmyoclonic seizures ex-
perienced a statistically signiﬁcant 60% reduction
in their frequency. Although not statistically sig-
niﬁcant, the reductions in the frequency of tonic,
atonic, and clonic seizures are clinically important.
Reductions in the frequency of such seizures lessen
the likelihood of patient injury.
This study used two techniques to enhance the
accuracy of the information that was collected.
The ﬁrst technique assured that the patients par-
ticipating in the study were properly classiﬁed
as having a generalized seizure syndrome by us-
ing video monitoring to establish and verify the
seizure syndrome and seizure type experienced by
each patient. The second technique involved as-
suring accurate seizure counts and classiﬁcation in
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patient seizure diaries. Before the patients were
implanted with the VNS therapy device, caregivers
and family members observed videotapes of the
patient as the various types of seizures occurred.
Implementing these techniques helped assure the
quality of the study data.
A deﬁnite strength of this study was that AEDs and
their dosages remained constant throughout the
reported evaluation period. During the long-term,
open label phases of the clinical trials of VNS ther-
apy for epilepsy, physicians were allowed to adjust
AEDs and their dosages. Long-term follow-up of
67 patients with reported AED changes in the E01
through E04 clinical trials showed the number of
AEDs had decreased for 12 patients after the ﬁrst
year and for 18 patients after the second year,
and had increased for three patients after the ﬁrst
year and eight patients after the second year.8
Such changes in AED therapy invite speculation re-
garding the factors that might inﬂuence reductions
in seizure frequency or severity. Because AEDs
and dosages remained constant, the reductions in
seizure frequency and severity noted in the cur-
rent study can be attributed to the effects of VNS
therapy. To our knowledge, this study is the longest
prospective investigation of VNS therapy during
which concurrent AEDs and their dosages were not
changed.
Only 16 patients participated in this study and
the duration of follow-up ranged from 12 to 21
months, factors that limit our ability to draw pre-
cise comparisons with previously published results
of VNS therapy. Despite these limitations, this
study supports previous ﬁndings that VNS therapy
is effective for treating generalized seizures. Be-
cause epilepsy surgery is not typically an option
for patients with generalized epilepsy, the pos-
sibility of seizure reductions with VNS therapy is
particularly important. As shown in this study, the
statistically signiﬁcant reduction in overall seizure
frequency and the reduced risk of injury during
severe seizures merit consideration of VNS therapy
for patients with pharmacoresistant generalized
seizure syndromes.
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